Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

10.05 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89Bio Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
The Latest Analyst Ratings for 89bio
Via Benzinga
Analyst Ratings for 89bio
Via Benzinga
BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
Via Benzinga
Why Akero Therapeutics Stock Is Crashing Today
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX). 
Via The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Gain; PepsiCo Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
What 6 Analyst Ratings Have To Say About 89bio
Via Benzinga
Analyst Ratings for 89bio
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From 89bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to... 
Via Benzinga
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
From 89bio, Inc.
Via GlobeNewswire
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
First FGF21 analog to enter Phase 3 development 
From 89bio, Inc.
Via GlobeNewswire
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.